Skip to main content
. Author manuscript; available in PMC: 2014 Oct 1.
Published in final edited form as: J Immunol. 2013 Aug 30;191(7):3519–3525. doi: 10.4049/jimmunol.1300789

Figure 5. MyD88 deficiency alleviates Aspergillus-induced skin barrier dysfunction.

Figure 5

(A) TEWL measurements taken the day after each patch removal (n=6–8 mice/group; Mean±SEM; 2-way ANOVA with Bonferroni post-tests ***p<0.001). (B) Epidermal thickness was assessed by morphometric analysis. (C) Asp-specific IgG1 plasma levels after the 3rd Aspergillus patch. (D) IL4 and IL17A skin levels. (E) Asp-stimulated lymph node cell secretion of IL4 and IL17A was assessed by ELISA. (F) S100A8, IL1β, IL-6 and CXCL2 skin mRNA levels were assessed by quantitative real-time PCR after the 3rd patch (n=3–6 mice/group). Representative results from 2 separate experiments (*p<0.05, **p<0.01, ***p<0.001 one way ANOVA with Bonferroni’s Multiple Comparison Test).